idarubicin has been researched along with Aplasia Pure Red Cell in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chalandon, Y; Helg, C; Stalder, M; Verholen, F | 1 |
1 other study(ies) available for idarubicin and Aplasia Pure Red Cell
| Article | Year |
|---|---|
Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion.
Topics: ABO Blood-Group System; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Group Incompatibility; Blood Transfusion; Combined Modality Therapy; Cytarabine; Drug Resistance; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Killer Cells, Natural; Leukemia, Myelomonocytic, Acute; Leukocyte Transfusion; Male; Middle Aged; Plasmapheresis; Red-Cell Aplasia, Pure; Remission Induction; Rituximab; Transplantation, Homologous | 2004 |